Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

None of that explains why your hero felt the need to say that aviptadil had failed to meet its primary endpoint 8 months after it succeeded in meeting its endpoint.

Nothing I've said in this discussion should be interpreted as a defense of the developers of aviptadil or the drug itself. I was merely noting the deception offered up by CEO Ehrlich who inexplicably felt the need to incorrectly use that drug as an example in his explanation of how brilacidin might be included in an ACTIV trial, an idea he hasn't mentioned in the last 2 PRs and a Shareholder Update yet continues to be floated here.